Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer

NCT06427278 | Completed

• 1 other identifier: RHDIRB2020110301/2022
• Study Type: observational
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

Elucidate the role of lncRNA CCDC144NL-AS1, hsa-miR-143-3p, and HMGA2 protein as non-invasive epigenetic molecular biomarkers in liquid biopsy of CRC Egyptian patients, individually or as an interaction arm and in comparison, to the conventional protein TMs. In addition, the investigators investigated the potential role of lncRNA CCDC144NL-AS1 as a mediator for development and/or progression of the cancer phenotype as well as CRC metastasis and its relation to both hsa-miR-143-3p and HMGA2, clinically and in silico.

Conditions

Colorectal Cancer

Keywords

Colorectal cancer; lncRNA CCDC144NL-AS1; Hsa-miR-143-3p; HMGA2; Liquid biopsy; In silico analysis

Outcome Measures

Primary Outcomes (4)

• Expression pattern of ncRNAs in CRC patients and controls

  9 months

• HMGA2 protein concentration in CRC patients and controls

  12 months

• Association of the investigated ncRNAs and HMGA2 with clinicopathological features of CRC patients

  12 months

• Correlation between lncRNA CCDC144NL-AS1, hsa-miR-143-3p and HMGA2 and the conventional CRC TMs

  10 months

Study Arms (2)

Patient group

A total of 60 primary CRC treatment-naïve Egyptian patients admitted to the Dar Al Shefa Hospital, Cairo, Egypt, were enrolled in the study.

Healthy Control

30 age-matched and sex-matched apparently healthy volunteers, not receiving any medications or suffering from any disease, age range 30-60 years, were included as controls, male-to-female 1:1 (15/15). Control subjects were recruited randomly during routine check-up examinations for themselves or during blood donation.

Eligibility Criteria

• Age: 30 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients group A total of 60 primary CRC treatment-naïve Egyptian patients admitted to the Dar Al Shefa Hospital, Cairo, Egypt, were enrolled in the study. Control group 30 age-matched and sex-matched apparently healthy volunteers, not receiving any medications or suffering from any disease, age range 30-60 years, were included as controls, male-to-female 1:1 (15/15). Control subjects were recruited randomly during routine check-up examinations for themselves or during blood donation.

You may qualify if:

• CRC diagnosed patients that is clinically confirmed by colonoscopy, abdominal radio-imaging, and histopathologicaly.

You may not qualify if:

• individuals receiving chemotherapy, radiation, or undergone surgery
• patients with blood disorders
• patients with any cancer other than CRC.
• Individuals with inadequate data or missing histopathological diagnoses
• distant metastases

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Faculty of Pharmacy, Ain Shams University, Advanced Biochemistry Research Lab

Cairo, 11566, Egypt

Location

Related Publications (1)

• Abd El Fattah YK, Abulsoud AI, AbdelHamid SG, AbdelHalim S, Hamdy NM. CCDC144NL-AS1/hsa-miR-143-3p/HMGA2 interaction: In-silico and clinically implicated in CRC progression, correlated to tumor stage and size in case-controlled study; step toward ncRNA precision. Int J Biol Macromol. 2023 Dec 31;253(Pt 2):126739. doi: 10.1016/j.ijbiomac.2023.126739. Epub 2023 Sep 9.

  PMID: 37690651 RESULT

Related Links

• Related Info

Biospecimen

Retention: SAMPLES WITH DNA

Five milliliters of peripheral venous blood were withdrawn from controls and CRC patients, under strict sterile conditions, following standard international biosecurity safety procedures, into polymer gel clot activator vacutainers (Greiner Bio-One GmbH, Australia). At room temperature (25 ◦C), completely coagulated samples were centrifuged at 4000 rpm for 10 min. Sera obtained were aliquoted into three DNase/ RNase free Eppendorf tubes and stored at -80 ◦C for molecular analysis.

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Study Officials

• Nadia Hamdy, PhD

  Faculty of pharmacy Ain Shams University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: professor of biochemistry and molecular biology

Study Record Dates

• First Submitted: May 19, 2024
• First Posted: May 23, 2024
• Study Start: August 1, 2019
• Primary Completion: October 1, 2022
• Study Completion: January 1, 2023
• Last Updated: May 23, 2024

Record last verified: 2024-05

Locations

EG (1)